AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NYRADA INC-CDI

0.745

-0.075-9.15%

Volume:1.03M

Turnover:767.51K

Market Cap:182.24M

PE:-30.76

High:0.795

Open:0.795

Low:0.720

Close:0.820

52wk High:1.435

52wk Low:0.077

Shares:244.62M

Float Shares:102.11M

Volume Ratio:1.36

T/O Rate:1.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.024

EPS(LYR):-0.024

ROE:-112.32%

ROA:-55.85%

PB:50.95

PE(LYR):-30.76

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Despite currently being unprofitable, Nyrada (ASX:NYR) has delivered a 776% return to shareholders over 1 year

Simply Wall St.

Nyrada Receives Ethics Committee Nod to Start Drug Candidate Trial for Treatment of Patients With Heart Attack Injuries

MT Newswires Live

Nyrada Insiders May Regret Not Buying More, Market Cap Hits AU$207m

Simply Wall St.

Nyrada Inc.'s (ASX:NYR) stock price dropped 10% last week; individual investors would not be happy

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NYR.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NYR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","market":"AU","secType":"STK","nameCN":"NYRADA INC-CDI","latestPrice":0.745,"timestamp":1770354720000,"preClose":0.82,"halted":0,"volume":1026136,"delay":0,"changeRate":-0.0914634146341463,"nameEN":"NYRADA INC-CDI","floatShares":102113109,"shares":244616371,"eps":-0.024221,"marketStatus":"Market Closed","change":-0.075,"latestTime":"02-06 16:12:00 AEDT","open":0.795,"high":0.795,"low":0.72,"amount":767510,"amplitude":0.091463,"askPrice":0.765,"askSize":4884,"bidPrice":0.745,"bidSize":49383,"shortable":3,"etf":0,"ttmEps":-0.024221,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770591600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.82,"openAndCloseTimeList":[[1770332400000,1770354000000]],"volumeRatio":1.3635373069979506,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","floatShares":102113109,"roa":"-55.85%","roe":"-112.32%","lyrEps":-0.024221,"volumeRatio":1.3635373069979506,"shares":244616371,"dividePrice":0,"high":0.795,"amplitude":0.091463,"preClose":0.82,"low":0.72,"week52Low":0.077,"pbRate":"50.95","psRate":"76.04","week52High":1.435,"institutionHeld":0,"latestPrice":0.745,"committee":0.820001,"eps":-0.024221,"divideRate":0,"volume":1026136,"delay":0,"ttmEps":-0.024221,"open":0.795,"prevYearClose":1.12,"prevWeekClose":0.84,"prevMonthClose":0.84,"prevQuarterClose":1.12,"fiveDayClose":0.84,"twentyDayClose":1.37,"sixtyDayClose":0.78},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NYR.AU\",params:#limit:5,,,undefined,":[{"date":"2023-07-28","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690502400000,"name":null,"time":"","dateTimestamp":1690466400000,"actualEps":null},{"date":"2023-04-29","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1682726400000,"name":null,"time":"","dateTimestamp":1682690400000,"actualEps":null},{"market":"AU","date":"2022-08-29","symbol":"NYR.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1661695200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NYR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NYR.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609469855","title":"Despite currently being unprofitable, Nyrada (ASX:NYR) has delivered a 776% return to shareholders over 1 year","url":"https://stock-news.laohu8.com/highlight/detail?id=2609469855","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609469855?lang=en_us&edition=fundamental","pubTime":"2026-02-07 04:41","pubTimestamp":1770410493,"startTime":"0","endTime":"0","summary":"Nyrada Inc. ( ASX:NYR ) shareholders might be rather concerned because the share price has dropped 46% in the last...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/despite-currently-being-unprofitable-nyrada-asxnyr-has-deliv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/despite-currently-being-unprofitable-nyrada-asxnyr-has-deliv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","NYR.AU"],"gpt_icon":0},{"id":"2601331403","title":"Nyrada Receives Ethics Committee Nod to Start Drug Candidate Trial for Treatment of Patients With Heart Attack Injuries","url":"https://stock-news.laohu8.com/highlight/detail?id=2601331403","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601331403?lang=en_us&edition=fundamental","pubTime":"2026-01-08 09:25","pubTimestamp":1767835551,"startTime":"0","endTime":"0","summary":"Nyrada  received approval from the Human Research Ethics Committee to start the Phase IIa clinical randomised, double-blind, placebo-controlled, multicenter trial of its small-molecule inhibitor Xolatryp in the treatment of myocardial ischemia reperfusion injury in patients suffering a heart attack, according to a Thursday filing with the Australian bourse.The trial will evaluate the safety and preliminary efficacy of Xolatryp in treating the injury in about 200 patients, the filing said.It will also evaluate multiple secondary efficacy signals, including cardiac function and extent of cardiac injury, the filing added.The company expects to start patient recruitment and dosing in March for the trial, the filing added.It expects to complete the trial within 18 months after the patient is dosed.Shares of the company rose 2% in recent Thursday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"gpt_icon":0},{"id":"2594287207","title":"Nyrada Insiders May Regret Not Buying More, Market Cap Hits AU$207m","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287207","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594287207?lang=en_us&edition=fundamental","pubTime":"2025-12-25 11:34","pubTimestamp":1766633662,"startTime":"0","endTime":"0","summary":"Last week, Nyrada Inc. ( ASX:NYR ) insiders, who had purchased shares in the previous 12 months were rewarded...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/nyrada-insiders-may-regret-not-buying-more-market-cap-hits-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/nyrada-insiders-may-regret-not-buying-more-market-cap-hits-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2584901886","title":"Nyrada Inc.'s (ASX:NYR) stock price dropped 10% last week; individual investors would not be happy","url":"https://stock-news.laohu8.com/highlight/detail?id=2584901886","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584901886?lang=en_us&edition=fundamental","pubTime":"2025-11-20 08:48","pubTimestamp":1763599721,"startTime":"0","endTime":"0","summary":"Key Insights Nyrada's significant individual investors ownership suggests that the key decisions are influenced by...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/nyrada-incs-asxnyr-stock-price-dropped-10-last-week-individu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/nyrada-incs-asxnyr-stock-price-dropped-10-last-week-individu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","NYR.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NYR.AU\",params:#limit:6,delay:true,,,undefined,":[]}}